NOxy Chairman Thomas L. Olds Jr. discusses why the company is focused on chronic wounds and the human burden created when care repeatedly manages a wound without achieving durable healing.
We don’t want to be in the business of treating chronic wounds. We want to be the people who heal chronic wounds.
The statement expresses NOxy’s mission and development objective. It is not a claim that an investigational product has been proven to heal wounds. NOX1416 has not been approved by FDA, and its safety and effectiveness have not been established.